Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

CTA and CPO survey from Horizon in wake of MF Global and PFG liquidations

Wednesday, October 31, 2012
Opalesque Industry Update - Horizon Cash Management said it will distribute a survey to commodity trading advisors (CTAs) and commodity pool operators (CPOs) designed to document the impact of the MF Global and Peregrine Financial Group (PFG) liquidations on the managed futures industry and its investors. The survey will go out October 31, marking the one-year anniversary of the MF Global meltdown.

Diane Mix Birnberg, Horizon Founder and Chairman, said, “I have witnessed ten bankruptcies of futures commission merchants (FCMs) in my 30-year career. Nothing, however, came close to the magnitude of the implosion created by MF Global and the additional damage caused by the PFG meltdown, a mere nine months later.”

Horizon said the survey will seek answers to important questions including:

  • How have CTAs and CPOs been impacted by these events?
  • What do CTAs and CPOs require in order to restore trust in their own businesses and with customers in the futures industry?
  • What regulations, rules, procedures and safeguards are needed to restore faith in customer fund segregation and the CTAs’ and CPOs’ ability to continue trading in times of severe market disruptions?

The survey, which aims to capture both quantitative and qualitative information, will be distributed to the entire universe of CTAs and CPOs globally in order to ensure a wide statistic base. All responses will remain anonymous. The Executive Summary will be distributed to regulators, government oversight authorities, futures exchanges, FCMs and the media worldwide in early 2013.

Press release

bc

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for